203 related articles for article (PubMed ID: 30223877)
1. Early toxicity and patient reported quality-of-life in patients receiving proton therapy for localized prostate cancer: a single institutional review of prospectively recorded outcomes.
Lee HJ; Macomber MW; Spraker MB; Bowen SR; Hippe DS; Fung A; Russell KJ; Laramore GE; Rengan R; Liao J; Apisarnthanarax S; Zeng J
Radiat Oncol; 2018 Sep; 13(1):179. PubMed ID: 30223877
[TBL] [Abstract][Full Text] [Related]
2. Five-Year Biochemical Results, Toxicity, and Patient-Reported Quality of Life After Delivery of Dose-Escalated Image Guided Proton Therapy for Prostate Cancer.
Bryant C; Smith TL; Henderson RH; Hoppe BS; Mendenhall WM; Nichols RC; Morris CG; Williams CR; Su Z; Li Z; Lee D; Mendenhall NP
Int J Radiat Oncol Biol Phys; 2016 May; 95(1):422-434. PubMed ID: 27084658
[TBL] [Abstract][Full Text] [Related]
3. Rectal Hydrogel Spacer Improves Late Gastrointestinal Toxicity Compared to Rectal Balloon Immobilization After Proton Beam Radiation Therapy for Localized Prostate Cancer: A Retrospective Observational Study.
Dinh TT; Lee HJ; Macomber MW; Apisarnthanarax S; Zeng J; Laramore GE; Rengan R; Russell KJ; Chen JJ; Ellis WJ; Schade GR; Liao JJ
Int J Radiat Oncol Biol Phys; 2020 Nov; 108(3):635-643. PubMed ID: 32035187
[TBL] [Abstract][Full Text] [Related]
4. Four-Year Outcomes From a Prospective Phase II Clinical Trial of Moderately Hypofractionated Proton Therapy for Localized Prostate Cancer.
Grewal AS; Schonewolf C; Min EJ; Chao HH; Both S; Lam S; Mazzoni S; Bekelman J; Christodouleas J; Vapiwala N
Int J Radiat Oncol Biol Phys; 2019 Nov; 105(4):713-722. PubMed ID: 31199994
[TBL] [Abstract][Full Text] [Related]
5. Initial report of the genitourinary and gastrointestinal toxicity of post-prostatectomy proton therapy for prostate cancer patients undergoing adjuvant or salvage radiotherapy.
Deville C; Jain A; Hwang WT; Woodhouse KD; Both S; Wang S; Gabriel PE; Christodouleas JP; Bekelman J; Tochner Z; Vapiwala N
Acta Oncol; 2018 Nov; 57(11):1506-1514. PubMed ID: 30028227
[TBL] [Abstract][Full Text] [Related]
6. Comparing bowel and urinary domains of patient-reported quality of life at the end of and 3 months post radiotherapy between intensity-modulated radiotherapy and proton beam therapy for clinically localized prostate cancer.
Bai M; Gergelis KR; Sir M; Whitaker TJ; Routman DM; Stish BJ; Davis BJ; Pisansky TM; Choo R
Cancer Med; 2020 Nov; 9(21):7925-7934. PubMed ID: 32931662
[TBL] [Abstract][Full Text] [Related]
7. Quality of life and toxicity from passively scattered and spot-scanning proton beam therapy for localized prostate cancer.
Pugh TJ; Munsell MF; Choi S; Nguyen QN; Mathai B; Zhu XR; Sahoo N; Gillin M; Johnson JL; Amos RA; Dong L; Mahmood U; Kuban DA; Frank SJ; Hoffman KE; McGuire SE; Lee AK
Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):946-53. PubMed ID: 24139077
[TBL] [Abstract][Full Text] [Related]
8. Long-term Toxicity and Health-related Quality of Life after Single-fraction High Dose Rate Brachytherapy Boost and Hypofractionated External Beam Radiotherapy for Intermediate-risk Prostate Cancer.
Shahid N; Loblaw A; Chung HT; Cheung P; Szumacher E; Danjoux C; Sankreacha R; Zhang L; Deabreu A; Mamedov A; Morton G
Clin Oncol (R Coll Radiol); 2017 Jul; 29(7):412-420. PubMed ID: 28190638
[TBL] [Abstract][Full Text] [Related]
9. Single-fraction high-dose-rate brachytherapy and hypofractionated external beam radiotherapy for men with intermediate-risk prostate cancer: analysis of short- and medium-term toxicity and quality of life.
Morton GC; Loblaw DA; Sankreacha R; Deabreu A; Zhang L; Mamedov A; Cheung P; Keller B; Danjoux C; Szumacher E; Thomas G
Int J Radiat Oncol Biol Phys; 2010 Jul; 77(3):811-7. PubMed ID: 19836166
[TBL] [Abstract][Full Text] [Related]
10. A pooled patient-reported outcomes analysis of moderately hypofractionated proton beam therapy and photon-based intensity modulated radiation therapy for low- or intermediate-risk prostate cancer.
Lukez A; Handorf E; Mendenhall NP; Henderson RH; Stish BJ; Davis BJ; Hallman M; Horwitz EM; Vapiwala N; Wong JK
Prostate; 2024 Mar; 84(4):395-402. PubMed ID: 38108113
[TBL] [Abstract][Full Text] [Related]
11. Patient-reported Quality of Life After Proton Beam Therapy for Prostate Cancer: The Effect of Prostate Size.
Goenka A; Newman NB; Fontanilla H; Cahlon O; Chon B; Tsai H; Hug E; Brown C; Vargas C; Parikh RR
Clin Genitourin Cancer; 2017 Dec; 15(6):704-710. PubMed ID: 28412047
[TBL] [Abstract][Full Text] [Related]
12. Patient-reported Outcomes and Late Toxicity After Postprostatectomy Intensity-modulated Radiation Therapy.
Akthar AS; Liao C; Eggener SE; Liauw SL
Eur Urol; 2019 Nov; 76(5):686-692. PubMed ID: 31113644
[TBL] [Abstract][Full Text] [Related]
13. A case-matched study of toxicity outcomes after proton therapy and intensity-modulated radiation therapy for prostate cancer.
Fang P; Mick R; Deville C; Both S; Bekelman JE; Christodouleas JP; Guzzo TJ; Tochner Z; Hahn SM; Vapiwala N
Cancer; 2015 Apr; 121(7):1118-27. PubMed ID: 25423899
[TBL] [Abstract][Full Text] [Related]
14. Five-year outcomes from 3 prospective trials of image-guided proton therapy for prostate cancer.
Mendenhall NP; Hoppe BS; Nichols RC; Mendenhall WM; Morris CG; Li Z; Su Z; Williams CR; Costa J; Henderson RH
Int J Radiat Oncol Biol Phys; 2014 Mar; 88(3):596-602. PubMed ID: 24521677
[TBL] [Abstract][Full Text] [Related]
15. Urinary functional outcomes and toxicity five years after proton therapy for low- and intermediate-risk prostate cancer: results of two prospective trials.
Henderson RH; Hoppe BS; Marcus RB; Mendenhall WM; Nichols RC; Li Z; Su Z; Morris CG; Williams CR; Costa J; Mendenhall NP
Acta Oncol; 2013 Apr; 52(3):463-9. PubMed ID: 23477359
[TBL] [Abstract][Full Text] [Related]
16. Preliminary exploration of clinical factors affecting acute toxicity and quality of life after carbon ion therapy for prostate cancer.
Zhang Y; Li P; Yu Q; Wu S; Chen X; Zhang Q; Fu S
Radiat Oncol; 2019 Jun; 14(1):94. PubMed ID: 31164172
[TBL] [Abstract][Full Text] [Related]
17. Patient reported outcomes among treatment modalities for prostate cancer.
Johnson ME; Zaorsky NG; Martin JM; Ruth K; Greenberg RE; Uzzo RG; Hayes SB; Smaldone MC; Kutikov A; Viterbo R; Chen DY; Hallman MA; Sobczak ML; Horwitz EM
Can J Urol; 2016 Dec; 23(6):8535-8545. PubMed ID: 27995848
[TBL] [Abstract][Full Text] [Related]
18. Stereotactic body radiation therapy (SBRT) for prostate cancer in men with large prostates (≥50 cm(3)).
Janowski E; Chen LN; Kim JS; Lei S; Suy S; Collins B; Lynch J; Dritschilo A; Collins S
Radiat Oncol; 2014 Nov; 9():241. PubMed ID: 25398516
[TBL] [Abstract][Full Text] [Related]
19. Phase 2 trial of guideline-based postoperative image guided intensity modulated radiation therapy for prostate cancer: Toxicity, biochemical, and patient-reported health-related quality-of-life outcomes.
Berlin A; Cho E; Kong V; Howell KJ; Lao B; Craig T; Bayley A; Chung P; Gospodarowicz M; Warde P; Catton C; Bristow RG; Ménard C
Pract Radiat Oncol; 2015; 5(5):e473-e482. PubMed ID: 25899220
[TBL] [Abstract][Full Text] [Related]
20. Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Early toxicity and quality-of life results from a randomized phase II clinical trial of one fraction of 19Gy or two fractions of 13.5Gy.
Morton G; Chung HT; McGuffin M; Helou J; D'Alimonte L; Ravi A; Cheung P; Szumacher E; Liu S; Al-Hanaqta M; Zhang L; Mamedov A; Loblaw A
Radiother Oncol; 2017 Jan; 122(1):87-92. PubMed ID: 27823821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]